Repotrectinib (Augtyro) Complete Medication Guide 2026: Import Original Drug Price, Eligible Patients & Full Usage Information

　　Repotrectinib is a highly selective oral multi-target tyrosine kinase inhibitor,marketed as AUGTYRO,primarily used for treating adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer(NSCLC).The drug effectively blocks tumor growth signaling pathways by precisely inhibiting ROS1 and NTRK fusion-related tyrosine kinases,suppressing cancer cell proliferation and spread.

　　1.Drug Origin:Imported Original Product

　　Repotrectinib was originally developed by American company Turning Point Therapeutics,which was acquired by Bristol-Myers Squibb(BMS)in 2022.Currently manufactured by BMS's Canadian subsidiary Patheon Inc.,it is classified as an imported original drug.No domestic generic versions are currently approved in mainland China.Patients in China use the original imported medication.

　　2.Domestic Supply Status

　　Repotrectinib has been officially launched in China.Patients can purchase it at hospital pharmacies or retail pharmacies domestically.China approval date was May 11,2024,approved by the National Medical Products Administration through priority review and approval procedure.US approval date was November 15,2023.

　　Drug specification is 40mg×120 capsules/box.Purchase requires a physician's prescription to ensure rational medication use and safety.Repotrectinib is now stably supplied nationwide.Patients can purchase through legitimate medical institutions or designated pharmacies with a valid prescription.

　　3.Pricing Information

　　The domestic original drug price of Repotrectinib is approximately five thousand yuan or more.Specific prices vary depending on region and procurement channels.Patients are advised to consult regular medical institutions for specific pricing and obtain accurate medication purchase information.

　　4.Generic Drug Status

　　Currently,there are Laos generic versions available abroad,priced at approximately two thousand yuan or more.Drug ingredients are basically consistent with domestic original drugs,but no generic drugs have been launched in China yet.Globally,only the original branded version of Repotrectinib exists with no officially approved generic versions.

　　So-called Laos generic versions circulating in the market are NOT approved by China's NMPA and carry quality and safety risks.Patients are still advised to prioritize domestic original drugs to ensure efficacy and safety when using,and carefully choose unapproved medication channels.

　　5.Eligible Patients&Prerequisites

　　Repotrectinib is suitable for patients with ROS1-positive advanced non-small cell lung cancer and NTRK fusion-positive advanced solid tumors.The main indication is adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer(NSCLC).

　　Genetic testing is required before medication to confirm target status,ensuring drug targeting and treatment effectiveness.Prerequisites before use include:confirm ROS1 fusion-positive status through genetic testing;treatment plan evaluated by oncology specialists;sign informed consent form and understand potential adverse reactions.

　　Clinical efficacy data shows median progression-free survival of approximately 35.7 months,objective response rate can reach over 90%,and shows good efficacy even in patients resistant to prior treatments.

　　6.Safety Reminders

　　This is a prescription drug and must be used under physician supervision.Regular monitoring of liver function and blood counts during treatment.Seek medical attention promptly for severe adverse reactions.Contraindicated in pregnant and breastfeeding women.

　　Patients should strictly follow medical advice for medication and cannot adjust dosage or stop medication on their own.If a dose is missed,handle according to physician recommendations and do not double dose.Avoid consuming grapefruit and grapefruit products during medication as they may affect drug metabolism.

　　Conclusion:As a next-generation ROS1 targeted therapy,Repotrectinib brings new hope to Chinese lung cancer patients.Patients are advised to seek treatment at legitimate medical institutions and follow professional physician guidance to ensure medication safety and efficacy.After confirming indications through genetic testing,standardized medication under physician guidance can achieve better treatment outcomes.